Daré Bioscience Croissance future
Future contrôle des critères 5/6
Daré Bioscience devrait augmenter ses bénéfices et ses revenus de 62.5% et de 57.7% par an respectivement, tandis que le BPA devrait croître de croître de 61% par an.
Informations clés
62.5%
Taux de croissance des bénéfices
60.98%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 11.9% |
| Taux de croissance des recettes | 57.7% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 09 Apr 2026 |
Mises à jour récentes de la croissance future
Recent updates
Women’s Health Pipeline Risks Will Persist Yet Long Term Potential Will Eventually Emerge
Catalysts About Daré Bioscience Daré Bioscience develops women’s health products across sexual health, contraception, menopause, vaginal health and infectious disease, with a focus on differentiated formulations built around known compounds. What are the underlying business or industry changes driving this perspective?
Women’s Health Pipeline And Dual 503B Pathway Will Transform Long Term Earnings Potential
Catalysts About Daré Bioscience Daré Bioscience focuses on developing and commercializing women’s health products across sexual health, contraception and menopause. What are the underlying business or industry changes driving this perspective?
Women’s Health Platform And 503B Launches Will Reshape Long-Term Outlook
Catalysts About Daré Bioscience Daré Bioscience is a women's health company focused on developing and commercializing clinically supported products across sexual health, contraception, menopause and vaginal health. What are the underlying business or industry changes driving this perspective?We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Daré Bioscience (NASDAQ:DARE) is trading 6.5% higher after the company announced positive data from its Phase 1/2 clinical trial of investigational intravaginal ring, DARE-HRT1, to treat the vasomotor symptoms and genitourinary syndrome associated with menopause. The drug is designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy regimen. The topline data from the study showed improvement in both vasomotor symptoms as well as vaginal symptoms of menopause. The primary objective or the main goal of the study was to demonstrate the safety, tolerability, and pharmacokinetics (PK) of two different dose combinations over 12 weeks of use. The company said the levels of estradiol released from both the lower and higher dose formulation of DARE-HRT1 evaluated in the study achieved statistically significant improvement. Menopausal symptoms, including hot flashes and night sweats, were reduced compared with baseline in both DARE-HRT1 dose groups. The topline PK data from the study will be available later in Q4.Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Daré Bioscience (NASDAQ:DARE) is trading 5.3% higher after the U.S. Food and Drug Administration approved its investigational device exemption (IDE) application to conduct an efficacy study of investigational hormone-free monthly intravaginal contraceptive, Ovaprene. The IDE approval will mean the FDA determined that the company provided sufficient data to support the initiation and conduct of the study. The submission included the results of the postcoital test clinical study of Ovaprene, in which the therapy prevented sperm from entering the cervical canal across all women and all cycles evaluated. The company is targeting mid-year 2023 to begin study recruitment.Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Dare Bioscience (NASDAQ:DARE) said that based on an interim analysis of phase 2b data for its sildenafil cream for female sexual arousal disorder, enrollment in the study will complete in Q4. Total enrollment will be 150 women. The company anticipates a top-line data announcement in Q2 2023. Sildenafil is the active ingredient in Viagra, a pill approved for erectile dysfunction. Dare (DARE) noted that its sildenafil cream is designed to be applied to the vaginal tissue just prior to intercourse to increase blood flow directly to the tissue. Seeking Alpha Quant Rating views Dare (DARE) as a hold with high marks for growth and revisions.Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Women health firm Daré Bioscience (NASDAQ:DARE) announced an exclusive license agreement with clinical-stage biopharma firm Organon (NYSE:OGN) to commercialize Xaciato, DARE's treatment of bacterial vaginosis in patients 12 years of age and older. Under the agreement, Daré will receive a $10M upfront payment from Organon and is eligible to receive potential milestone payments of up to $182.5M and tiered double-digit royalties based on net sales. Xaciato will be commercially available in the U.S. in Q4, DARE said. The companies entered into the agreement on March 31.Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Diving Back Into Daré Bioscience Again
Today, we revisit women's health concern Daré Bioscience for the first time in nearly a year. This small cap concern just received its first FDA approval and is advancing other candidates in its pipeline. A full investment analysis follows in the paragraphs below.We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
While Daré Bioscience, Inc. ( NASDAQ:DARE ) might not be the most widely known stock at the moment, it led the NASDAQCM...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 134 | 69 | N/A | N/A | 2 |
| 12/31/2027 | 50 | 9 | N/A | N/A | 2 |
| 12/31/2026 | 0 | -19 | N/A | N/A | 2 |
| 12/31/2025 | 1 | -13 | -10 | -10 | N/A |
| 9/30/2025 | 0 | -17 | -7 | -6 | N/A |
| 6/30/2025 | 0 | -19 | -12 | -12 | N/A |
| 3/31/2025 | 0 | -2 | 6 | 7 | N/A |
| 12/31/2024 | 0 | -4 | 5 | 5 | N/A |
| 9/30/2024 | 2 | -4 | -9 | -8 | N/A |
| 6/30/2024 | 3 | -7 | -11 | -10 | N/A |
| 3/31/2024 | 3 | -29 | -30 | -30 | N/A |
| 12/31/2023 | 3 | -30 | -39 | -39 | N/A |
| 9/30/2023 | 1 | -41 | -37 | -37 | N/A |
| 6/30/2023 | N/A | -40 | -20 | -20 | N/A |
| 3/31/2023 | 10 | -31 | -22 | -22 | N/A |
| 12/31/2022 | 10 | -31 | -18 | -18 | N/A |
| 9/30/2022 | 10 | -25 | -22 | -22 | N/A |
| 6/30/2022 | 10 | -30 | -29 | -29 | N/A |
| 3/31/2022 | N/A | -40 | -33 | -33 | N/A |
| 12/31/2021 | N/A | -39 | -29 | -29 | N/A |
| 9/30/2021 | N/A | -38 | -28 | -28 | N/A |
| 6/30/2021 | N/A | -33 | -35 | -35 | N/A |
| 3/31/2021 | N/A | -30 | -27 | -27 | N/A |
| 12/31/2020 | N/A | -27 | -25 | -25 | N/A |
| 9/30/2020 | N/A | -23 | -20 | -20 | N/A |
| 6/30/2020 | N/A | -19 | -18 | -18 | N/A |
| 3/31/2020 | N/A | -16 | -17 | -17 | N/A |
| 12/31/2019 | N/A | -15 | -13 | -13 | N/A |
| 9/30/2019 | N/A | -14 | N/A | -12 | N/A |
| 6/30/2019 | N/A | -13 | N/A | -12 | N/A |
| 3/31/2019 | N/A | -12 | N/A | -11 | N/A |
| 12/31/2018 | N/A | -17 | N/A | -10 | N/A |
| 9/30/2018 | N/A | -23 | N/A | -9 | N/A |
| 6/30/2018 | N/A | -22 | N/A | -7 | N/A |
| 3/31/2018 | N/A | -19 | N/A | -5 | N/A |
| 12/31/2017 | N/A | -12 | N/A | -3 | N/A |
| 9/30/2017 | N/A | -3 | N/A | -2 | N/A |
| 6/30/2017 | N/A | -1 | N/A | 0 | N/A |
| 3/31/2017 | N/A | -1 | N/A | 0 | N/A |
| 12/31/2016 | N/A | -1 | N/A | 0 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: DARE devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 3.5% ).
Bénéfices vs marché: DARE devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.
Croissance élevée des bénéfices: DARE devrait devenir rentable dans les 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de DARE ( 57.7% par an) devrait croître plus rapidement que le marché US ( 11.7% par an).
Croissance élevée des revenus: Le chiffre d'affaires de DARE ( 57.7% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de DARE devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/14 06:39 |
| Cours de l'action en fin de journée | 2026/05/14 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Daré Bioscience, Inc. est couverte par 5 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Douglas Tsao | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |